InvestHK is committed to assisting enterprises from Mainland China and overseas in expanding international business opportunities through Hong Kong, including companies engaged in advanced therapy products. A Mainland biopharmaceutical technology company stated that Hong Kong performs well in intellectual property protection, while the research and development standards of the medical faculties at the citys two universities are also very high. Government support in technology and talent policies has further facilitated the companys development.

Anthony Wong, Head of Innovation and Technology and Life Sciences at InvestHK, said that Hong Kong amended its legislation in 2020 to clearly require that the manufacturing of advanced therapy products comply with the standards and framework of the Pharmaceutical Inspection Co-operation Scheme (PIC/S). The Pharmacy and Poisons Board of Hong Kong had already become a member of the scheme in 2016. As a result, Hong Kongs standards are now mutually recognized with those adopted by more than 50 member authorities.

He noted that when advanced therapy product companies conduct research and development in Hong Kong in compliance with PIC/S Good Manufacturing Practice standards, their clinical data can be recognized by more than 50 countries, including the European Union, the United Kingdom, Australia and Canada, thereby facilitating and accelerating their local registration processes in those markets. (ss/w)

AASTOCKS Financial News